UNSPSC 51432407: Zofenopril calcium

This classification denotes an ace inhibitor with the molecular formula 2C22H22NO4S2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88ZQ329PU2, chemically known as l-proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-, calcium salt, (1(r*),2alpha,4alpha)- but more generally known as zofenopril calcium, which bears US NIH Compound Identifier 3033690. European Medicines Agency schedules Zofenopril calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05191MIG.

UNSPSC 51432407 Zofenopril calcium, a Commodity code, represents pharmaceutical ingredients and finished-dose medications procured by state and local governments for emergency medical services, health plans, and institutional pharmacy programs. State and local buyers under this code source specific pharmaceutical products through competitive sealed bids, cooperative purchasing agreements, and exploratory market-intelligence requests to supply fire departments, public health agencies, and state Medicaid or employee health benefit programs. The work involves supplying finished medications with defined strength, dosage form, and packaging; meeting expiration-date and shelf-life requirements; maintaining compliance with FDA, cGMP, and DSCSA standards; and delivering inventory within specified timeframes, often with provisions for expired-stock replacement or pickup.

Recent activity spans fire departments, state health agencies, and multistate cooperative purchasing organizations. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with epinephrine, labetalol, adenosine, and diltiazem products, with a response deadline of April 8, 2026 and an estimated contract value of $40,000; the award included a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, requiring manufacturers to supply products through three authorized wholesalers with effective dates of July 1, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for a Therapeutic Pharmacy Initiative. Geographic activity concentrates in the South (Florida, Texas) and Midwest (Minnesota, with Oregon participation through MMCAP), with cooperative purchasing mechanisms extending multistate reach.